Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Styrelsen beslutar om genomförande av redan kommunicerad riktad emission

Styrelsen för Initiator Pharma A/S (“Initiator” eller “Bolaget”) har idag, den 19 maj 2022, med stöd av bemyndigandet från den nyligen hållna extra bolagsstämman, beslutat att genomföra den riktade emissionen som kommunicerades via ett pressmeddelande den 13 april 2022. Den riktade emissionen tecknades av Linc AB och Adrigo Asset Management AB och tillför Bolaget cirka 20 MSEK före emissionskostnader.

Board of Directors decides on execution of already communicated directed issue

The Board of Directors of Initiator Pharma A/S (“Initiator” or “the Company”) has today, 19 May 2022, based on the authorization from the recently held Extraordinary General Meeting, decided to execute the directed issue which was communicated via a press release on 13 April 2022. The directed issue was subscribed by Linc AB and Adrigo Asset Management AB, and it will provide the Company with approx. SEK 20 million before issue costs.

INITIATOR PHARMA: Q1 2022 REPORT

Business highlights in Q1 2022 On January 20th the initiation of dosing in the IPTN2021 program Phase 1 to assess pain reducing effects in healthy volunteers was announced. On March 22nd it was…